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Abstract: Panitumumab is a fully humanized monoclonal antibody with a high degree of afﬁ  nity 
for the extracellular domain of the epidermal growth factor receptor. Phase II clinical evaluation of 
this drug, when administered as a single agent, in patients with metastatic colorectal cancer refrac-
tory to chemotherapy, demonstrated a modest objective radiographic response rate with acceptable 
toxicity; the most frequently observed side effect is rash. A randomized phase III study in subjects 
with chemotherapy-refractory metastatic colorectal cancer documented a progression-free survival 
advantage in subjects treated with panitumumab plus best supportive care versus best supportive 
care alone; a difference in survival was not observed, likely due to the high cross over rate. Primary 
tumor KRAS mutation analysis performed in this study indicated that the beneﬁ  t was conﬁ  ned to 
those patients whose tumors did not contain a KRAS mutation. Further studies with panitumumab 
will be required to develop biomarkers of response and to determine if panitumumab has a role in 
combination with cytotoxic chemotherapy. This article summarizes the current state-of-the-science 
knowledge on panitumumab therapy in the treatment of advanced colorectal cancer.
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Introduction
The epidermal growth factor receptor (EGFR) is one of the HER tyrosine kinase growth 
factor receptor family which includes her-2/neu, EGFR3, and EGFR4; its natural 
ligands include transforming growth factor-alpha, epidermal growth factor, amphi-
regulin, and epiregulin. EGFR is a transmembrane glycoprotein with an extracellular 
ligand binding domain in addition to an intracellular tyrosine kinase activator. Identi-
ﬁ  ed ﬁ  rst in 1962, its role in cellular function has not been completely elucidated; it is 
known to be an important agent in cellular proliferation, angiogenesis, and protection 
of the cell from potentially lethal toxic insults. Once ligand binds to the EGFR it either 
homodimerizes (with another EGFR monomer) or heterodimerizes (with another EGFR 
family monomer) (Sako et al 2000). This dimerization leads to autophosphorylation 
of several tyrosine kinase residues with subsequent downstream activation of intracel-
lular signaling pathways important in cell cycle growth regulation. Murine antibodies 
targeting EGFR, both agonist and antagonist, were generated by Drs. Gordon Sato 
and John Mendelsohn in the early 1980s (Mendelsohn 2002). Preclinical studies have 
demonstrated that these antagonist antibodies can bind to the EGFR, with a higher 
afﬁ  nity than the natural ligands, and by doing so interrupts proliferation of human 
cancer cells in vivo (Kawamoto et al 1983; Sato et al 1983).
Cetuximab
In order to better understand the development of panitumumab it is helpful to know 
the background and clinical development of the ﬁ  rst monoclonal antibody directed at Therapeutics and Clinical Risk Management 2008:4(6) 1222
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the EFGR approved by the US Food and Drug Administration 
(FDA) for the treatment of advanced refractory colorectal 
cancer. The chimeric antibody cetuximab (C225, Erbitux™), 
was derived from the first murine antibody M225 and 
demonstrated preclinical anti-cancer activity, both in human 
cancer tissue culture assays and in human cancer animal 
xenograft models (Olverholser et al 2000). Cetuximab was 
demonstrated to have signiﬁ  cant synergy with topoisomer-
ase II inhibitors such as irinotecan; in addition, preclinically 
it was demonstrated that cetuximab combined with irinotecan 
could inhibit tumor growth in DLD-1 and HT-29 human 
colorectal cancer murine xenograft models, where each agent 
alone did not control tumor growth (Prewett et al 2002). 
This ability to reverse irinotecan resistance in preclinical 
tumor models has also been demonstrated with oxaliplatin 
(Prewett et al 2007). The EGFR has been demonstrated to 
be an important pathway in the development of colorectal 
cancer progression and metastasis therefore making it an 
attractive target for anticancer therapy in colorectal cancer 
(Lockhart et al 2005).
Clinical trials have subsequently shown that in subjects 
with metastatic colorectal cancer, refractory to at least one 
line of prior cytotoxic therapy, the use of cetuximab mono-
therapy was associated with a radiographic partial response 
(PR) in approximately 9% of cases (utilizing the modiﬁ  ed 
World Health Organization criteria for radiographic assess-
ment) (Saltz et al 2004). A randomized phase II study assign-
ing subjects to either cetuximab monotherapy or cetuximab 
combined with irinotecan, conﬁ  ned to subjects with advanced 
colorectal cancer refractory to prior irinotecan therapy, with 
tumor expression of EGFR as demonstrated by immunohis-
tochemistry (IHC), conﬁ  rmed the monotherapy activity of 
this drug in patients with advanced colorectal cancer with a 
radiographic PR rate of 10.8% and a combination therapy 
response rate of 22.9% (Cunningham et al 2004). Preclinical 
studies showing that EGFR inhibition by monoclonal anti-
body therapy in vitro can overcome chemotherapy resistance 
accurately predicted the clinical efﬁ  cacy of monoclonal 
EGFR inhibitors. EGFR monoclonal antibody inhibitors are 
the only approved therapy to date that has been clearly been 
shown to reverse chemotherapy resistance clinically.
Tumor EGFR inhibition can also be achieved by the 
use of small-molecule receptor tyrosine kinase inhibitors. 
Clinical trials of EGFR inhibition by receptor tyrosine 
kinase inhibitors has not led to the same degree of clinical 
efﬁ  cacy in colorectal cancer as observed with the use of 
EGFR-directed monoclonal antibody therapies (Keiholz et al 
2005; Rothenberg et al 2005). The basis for the differences 
in activity observed in clinical trials between these two 
classes of anti-EGFR therapies (monoclonal antibodies 
and receptor tyrosine kinase antagnonists) is not known 
although it suggests that the kinase independent functions 
for the receptor may be important in cancer progression 
and another possible mechanism of activity of monocloncal 
anti-EGFR therapy (Cocker et al 1994; Ewald et al 2003; 
Weihua et al 2008).
Panitumumab monotherapy 
in colorectal cancer
Panitumumab (ABX-EGF, Vectibix™) is a fully human-
ized, high affinity IgG2 monoclonal antibody directed 
against EFGR. To reduce the immunogenicity of murine 
monoclonal antibodies a fully humanized monoclonal 
antibody was rationally developed. Cetuximab consists of 
34% murine protein; the chimeric recombinant monoclonal 
antibodies can be immunogenic accounting for the higher 
rates of serious hypersensitivity reactions associated with 
the clinical use of cetuximab compared with panitumumab. 
In order to reduce the allergic reactions related to the murine 
element, a fully humanized monoclonal antibody directed at 
the EGFR, panitumumab, was developed. The major differ-
ences between cetuximab and panitumumab are illustrated 
in Table 1. Introducing human immunoglobulin genes into 
mice engineered to lack functional mouse immunoglobulin 
genes were used to create panitumumab. The practice for 
the nomenclature of the naming of monoclonal antibodies 
is outlined in Table 2.
Panitumumab binds to the EGFR with a higher afﬁ  nity 
than its natural ligands to prevent receptor dimerization and 
subsequent intracellular autophosphorylation. Preclinical 
studies documented its EGFR-dependent activity in xenograft 
models (Yang et al 2001). A phase I study conducted in 
subjects with advanced refractory solid tumors expressing 
EGFR by IHC found the drug to be well tolerated and did not 
identify a maximum tolerated dose (subjects were treated up 
to a dose of 9.0 mg/kg administered every 21 days) (Weiner 
et al 2008). No hypersensitity reaction was observed in the 
Table 1 Comparison of cetuximab and panitumumab
Cetuximab Panitumumab
Molecular weight 152.1 kDa 147 kDa
% Murine 34% 0%
Kd EGFR 3.4 × 10−10 5 × 10−11
Half-life ∼112 hours ∼180 hours
Grade ¾ hypersensitivity 3% 1%Therapeutics and Clinical Risk Management 2008:4(6) 1223
Panitumumab in colorectal cancer
97 patients treated and premedication nor a loading dose was 
required. The pharmacokinetics demonstrated that panitu-
mumab could be ﬂ  exibly dosed from a weekly, fortnightly or 
on an every-3-week schedule, making it attractive to combine 
with other cytotoxic chemotherapy regimes. Interestingly 
5 patients obtained conﬁ  rmed partial responses and 19 had 
stable disease on this phase I trial.
This significant clinical activity seen in this phase 
I dose-ﬁ  nding study was conﬁ  rmed in a larger multicenter 
phase II study of panitumumab administered to subjects with 
metastatic, EGFR expressing tumors refractory to standard 
chemotherapy, at a dose of 2.5 mg/kg weekly 8 out of 9 weeks 
(Hecht et al 2007). Out of 148 patients treated there was a 
9% objective radiographic response rate and a 29% disease 
stabilization rate; therapy was well tolerated with side effects 
mainly related to skin toxiocity, only 4 subjects withdrawing 
from treatment due to toxicity. One patient experienced a 
hypersensitivity reaction but went on to receive additional 
cycles of therapy with appropriate premedication.
The progression-free survival (PFS) beneﬁ  t associated 
with the use of panitumumab in chemotherapy refractory 
disease has now been conﬁ  rmed by a large, randomized 
study of patients with refractory EGFR-expressing metastatic 
colorectal cancer (Van Cutsem et al 2007). The trial design 
compared the efﬁ  cacy and safety of panitumamab plus best 
supportive care (BSC) to BSC alone in 463 patients whose 
tumors had demonstrated expression of EGFR by IHC (at 
least 1% or more EGFR tumor cell membrane staining). 
Subjects on the experimental treatment arm received pani-
tumumab 6 mg/kg by vein every two weeks until disease 
progression. A provision in the study was made to allow 
cross over of those patients who progressed on BSC alone 
to subsequently receive panitumumab. Seventy-ﬁ  ve percent 
(174) of the subjects in the BSC alone arm crossed over to 
the panitumumab plus BSC arm; 67% of the 463 patients 
had colon cancer with the remainder having rectal cancer. 
All patients had received 2 or more lines of prior chemo-
therapy with disease progression; of note patients in whom 
chemotherapy was discontinued due to toxicity were not 
eligible for study enrollment unless that had documented dis-
ease progression while on chemotherapy. The primary study 
endpoint was met with a statistically signiﬁ  cant prolongation 
in PFS in favor of the experimental arm. There was also 
noted to be a statistically signiﬁ  cant higher radiographic 
response rates in the panitumumab treated group (10%) 
compared with the control group (0%). A difference in overall 
survival was not observed. The effect of panitumumab on 
survival was likely obscured by the cross-over design of the 
trial; 76% of the subjects assigned to the control arm (BSC) 
crossed over to treatment with panitumumab upon progres-
sion. The favorable effect on PFS was observed in all patient 
groups irrespective of age, performance status, number of 
metastatic sites, number of previous treatments or levels of 
EGFR over-expression. Based on the PFS advantage seen 
with the use of panitumumab compared with BSC alone in 
the treatment of advanced refractory colorectal cancer, pani-
tumumab was approved by the FDA on September 27, 2006 
for the monotherapy treatment of chemotherapy-refractory 
metastatic colorectal cancer (FDA 2006).
The clinical outcomes and toxicity observed across 
clinical trials of cetuximab and panitumumab are quite 
similar: the main difference is the lower rate of serious 
(grade 3 or 4) hypersensitivity reactions (2.4% versus 0.5%). 
This difference is presumably to be due to the chimeric versus 
human nature of the antibodies. It is not known whether the 
difference in IgG subclass between the molecules leads to a 
different immunologic effect on the patient receiving them 
or whether this effect is clinically signiﬁ  cant.
Management of panitumumab rash
Dermopathy is the most common toxicity experienced by 
patients on panitumumab therapy, and all patients experi-
ence some form of skin change, the most common being dry 
skin (xerosis) (Mitchell et al 2007). Over 80% of patients 
reported on clinical trials develop a sterile acneiform der-
matitis as a consequence of cutaneous EGFR inhibition. Its 
distribution is primarily on the face and trunk but can arise 
in other areas particulary those exposed to the sun. For this 
reason avoidance of sun exposure is an important part of 
managing panitumumab skin reactions. Although the rash is 
not infectious the disruption of the skin barrier may lead to 
secondary staphylococcal skin infection or impetigination. 
Of interest the degree of skin reaction observed appears to 
Table 2 Monoclonal antibody nomenclature (Guidelines on the 
Use of INNs 1997)
Target Source Sufﬁ  x
-co(l)- colonic tumor -u- human
-mab
-me(l)- melanoma -o- mouse
-ma(r)- mammary tumor -a- rat
-go(t)- testicular tumor -e- hamster
-go(v)- ovarian tumor -i- primate
-pr(o)- prostate tumor -xi- chimeric
-tu(m)- miscellaneous tumor -zu- humanized
Example: Ce-tu-xi-mab – tumor – chimeric
Pani-tum-u-mab – tumor – human.Therapeutics and Clinical Risk Management 2008:4(6) 1224
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be a phamacodynamic marker of anti-EGFR efﬁ  cacy; this 
has been observed with cetuximab in a number of different 
disease types in which their use has been studied (Saltz et al 
2003). This observation has led to an experimental strategy 
of dose escalation of cetuximab therapy to rash in patients 
with colorectal cancer; this strategy is not currently recom-
mended as standard of care (Tejpar et al 2007).
The management of the skin toxicity is largely empiric 
and supportive (Fox et al 2006). Topical steroids have been 
used for their anti-inﬂ  ammatory properties. Systemic and 
topical antibiotics have been used to treat the secondary 
infection; the use of agents such as doxycyline may also 
have an immunological basis by their inhibition of neutro-
phic recruitment to the skin. Xerosis is treated with topical 
hydrating lotions. The natural history of the acneiform rash 
is to gradually improve after 4 to 8 weeks of panitumumab 
therapy; after several months of therapy nail changes 
(parnonychia, desquamation of the distal digits) and tricho-
megaly occur. Due to the initial severity of the symptoms 
patients experience from anti-EGFR therapies, primary 
prophylaxis with sun barrier creams, hydrating lotions, and 
topical and systemic antibiotics have been studied (Mitchell 
et al 2008). Given the relatively low toxicity of prophylactic 
therapies, and the documented amelioration of symptomatic 
rash, their use is recommended.
Panitumumab combination therapy 
trials in colorectal caner
The monotherapy efﬁ  cacy and the ﬂ  exibility in dosing 
schedule initially made panitumumab an attractive 
agent to combine with other cytotoxic and anti-VEGF 
monoclonal antibody therapies with proven efficacy 
in metastatic colorectal cancer. Combination phase II 
studies of cytotoxic chemotherapy with panitumumab 
have shown an acceptable toxicity proﬁ  le. It has been 
combined safely with weekly bolus intravenous irinotecan, 
5-FU modulated by folinic acid (IFL) in addition to 
irinotecan, bolus 5-ﬂ  urouracil (5-FU) modulated by folinic 
acid and protracted venous infusion 5-FU, administered 
every 14 days (FOLFIRI) (Hecht et al 2006). In this study 
patients had a good performance status (ECOG 1) and 
had received no prior systemic chemotherapy for metastatic 
colorectal cancer. Panitumumab was given at a dose of 
2.5 mg/kg to 19 patients receiving IFL and 24 patients 
receiving FOLFIRI. This study demonstrated that 
panitumumab was reasonably well tolerated as combination 
therapy with FOLFIRI. Over half of the subjects receiving 
IFL had grade 3 or 4 diarrhea (Common Toxicity Criteria, 
version 2) compared with 5% of patients receiving FOL-
FIRI. All patients had some skin-related toxicity. A small 
percentage of patients treated with IFL also had hypoka-
lemia, fatigue and nausea, which was not present in those 
treated with FOLFIRI. The results of this phase II trial sug-
gested a possible role for panitumumab combined with cyto-
toxic chemotherapy in the ﬁ  rst-line treatment of colorectal 
cancer. This was studied in 2 phase III studies evaluating 
the ﬁ  rst-line use of panitumumab when combined with cyto-
toxic therapy alone and with combination cytotoxics and 
anti-VEGF monoclonal antibody therapy: the PACCE study 
(Panitumumab Advanced Colorectal Cancer Evaluation) 
and the PRIME study (Panitumumab Randomized Trial In 
Combination with Chemotherapy for Metastatic Colorec-
tal Cancer to Determine Efﬁ  cacy). In the PACCE study 
subjects with previously untreated metastatic surgically 
unresectable colorectal cancer received either FOLFOX4 
or FOLFIRI chemotherapy (at the investigator’s discretion) 
plus bevacizumab, and were subsequently randomized to 
receive to receive panitumumab or no anti-EGFR therapy 
(Hecht et al 2007). A pre-planned interim safety analysis 
of the oxaliplatin and bevacizumab-treated groups, which 
included 407 subjects who received panitumumab and 
405 subjects in the control arm showed no difference in 
radiographic response rates when evaluated by external 
review. There was a signiﬁ  cant difference in the medial PFS 
of 10.5 months in the control group versus 8.8 months in 
the experimental (panitumumab-treated) arm (p = 0.004). 
There was also increased toxicity in the panitumab treated 
arm with a higher rates of grade 3/4 diarrhea, dehydration, 
and infection observed. Based on the data obtained at this 
analysis the study was discontinued prematurely. Subse-
quent analysis of the irinotecan-treated subjects revealed 
similar ﬁ  ndings (Hecht et al 2008). Based on these data the 
combination of panitumab with cytotoxic chemotherapy 
and anti-VEGF therapy is not recommended outside of 
investigational trials. Primary tissue was available from 
the majority of subjects accrued to the PACCE trial and 
biomarker data from the oxaliplatin-treated subjects will be 
forthcoming. The results from this phase III panitumumab 
combination trial do not exclude future studies of panitu-
mumab in combination with cytotoxic and/or anti-VEGF 
therapies particularly in biomarker-directed trials enriched 
for subjects most likely to respond to panitumumab therapy. 
In the PRIME study subjects with previously untreated 
metastatic colorectal cancer were randomized to receive 
FOLFOX4 with or without panitumumab (6.0 mg/kg every Therapeutics and Clinical Risk Management 2008:4(6) 1225
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2 weeks). This trial has completed accrual with acceptable 
safety data reported; efﬁ  cacy data are anticipated to be 
presented in the near future (Siena et al 2008).
Biomarkers of anti-EGFR 
monoclonal antibody therapy
As a minority of subjects with advanced metastatic 
colorectal cancer have a signiﬁ  cant objective radiographic 
response following monoclonal antibody anti-EGFR ther-
apy, efforts to identify biomarkers of efﬁ  cacy have been 
undertaken. Although initial studies were designed based 
on the rationale that semiquantitative receptor expression 
measurement by means of IHC would identify subjects 
most likely to beneﬁ  t from anti-EGFR therapy, data from 
these early clinical trials did not demonstrate a correlation 
between degree of EGFR expression by IHC and radio-
graphic response rate. Subsequent clinical trials have not 
selected subjects for inclusion based on EGFR expression 
by IHC; data from some of these trials have shown that 
radiographic responses have occurred in subjects whose 
tumors have been shown to be EGFR negative by IHC 
(Chung et al 2005). Unlike non-small cell lung cancer, 
activating EGFR mutations are uncommonly described in 
colorectal cancers (Tsuchihashi et al 2005). EGFR gene 
copy number has been postulated to identify those subjects 
with colorectal cancer more likely to beneﬁ  t from anti-
EGFR monoclonal antibody therapy (Moroni et al 2005; 
Sartore-Bianchi et al 2007): additional analysis of these 
data suggest that a low EGFR copy number may be a better 
negative prognostic marker of anti-EGFR therapy. KRAS 
mutation status is known to be an independent adverse 
prognostic factor in colorectal cancer (Baurault et al 2008). 
Studies have shown that tumors without KRAS mutations 
are more likely to experience a radiographic PR or stable 
disease in response to EGFR monoclonal antibody therapy 
compared with those whose tumors had demonstrated 
KRAS mutation, suggesting that it may also be a predictive 
factor for efﬁ  cacy of EGFR monoclonal antibody therapy 
(cetuximab) in metastatic colorectal cancer (Leivre et al 
2006). Retrospective analysis of the primary tumors from 
the previously cited phase III trial of panitumumab plus 
BSC versus BSC (Van Cutsem et al 2007) was undertaken 
to evaluate for KRAS mutation status and correlate this 
status with clinical outcome (Amado et al 2008). This 
analysis revealed no beneﬁ  t to the use of panitumumab, in 
terms of PFS, overall survival, or radiographic response rate 
compared with the BSC arm: the beneﬁ  t was conﬁ  ned to 
those subjects whose primary tumors had wild type KRAS 
mutation status. These data suggest that the efﬁ  cacy of pani-
tumuab is conﬁ  ned to tumors with wild type KRAS muta-
tion status: based on this data set the European regulatory 
authorities (EMEA) have approved the use of panitumumab 
in patients with advanced chemotherapy refractory tumors 
with wild-type KRAS mutation status (EMEA 2007).
Similar analysis in patients treated with cetuximab 
monotherapy suggest a lack of beneﬁ  t in those patients 
with mutant KRAS tumors. Biomarker data are now 
available regarding the beneﬁ  t of anti-EGFR therapy in 
combination with cytotoxic chemotherapy. In a phase III 
front-line study of FOLFOX-4 with and without cetuximab 
(the OPUS trial) there was a beneﬁ  t in progression-free 
survival from the addition of cetuximab to chemotherapy 
in those patients with wild-type KRAS tumors (7.7 versus 
7.2 months, p = 0.02) whereas there was no beneﬁ  t in 
those patients with mutated KRAS (5.5 versus 8.6 months, 
p = 0.02) (Bokemeyer et al 2008). The biomarker data from 
the CRYSTAL study (a ﬁ  rst-line phase III study comparing 
FOLFIRI to FOLFIRI plus cetuximab) also showed that 
the clinical beneﬁ  t from the addition of cetuximab therapy 
was limited to those patients with non-mutant KRAS tumors 
(Van Cutsem et al 2008).
These data suggest that the use of panitumumab should 
be as a single agent and limited to those patients with 
metastatic colorectal cancer who have wild-type KRAS 
refractory to cytotoxic chemotherapy; panitumumab therapy 
is not recommended in patients whose tumors have KRAS 
mutations. The efﬁ  cacy of panitumumab in combination 
therapy with cytoxic or other biologic agents is still under 
evaluation and is considered experimental at this time.
Conclusions
Panitumumab has been shown to be effective as monotherapy 
in patients with chemotherapy-refractory metastatic 
colorectal cancer whose tumors have wild-type KRAS: it 
does not appear to have efﬁ  cacy in those with mutant KRAS. 
Data at this time do not support its use in combination 
therapy. It is generally well tolerated with rash as the 
primary side effect. As with cetuximab the degree of skin 
toxicity may be a surrogate marker for anti-tumor activity. 
Because panitumumab is a fully human monoclonal 
antibody, it can be administered without hypersensitivity 
premedication. Continued clinical studies are warranted to 
determine the efﬁ  cacy the combination of panitumumab with 
chemotherapy, as well as its role with other novel targeted 
agents, in patients with wild-type KRAS tumors both in the 
metastatic and adjuvant setting.Therapeutics and Clinical Risk Management 2008:4(6) 1226
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